Global Diabetes Medicine Sales by Country

In 2023, Croatia led in diabetes medicine sales per capita at $146, showing a modest 3.71% year-on-year growth. Norway, while second at $60.8 per capita, experienced a robust 19.07% increase. Greece at $51.5 saw a slight 2.28% rise. The Czech Republic ($36.3) and Australia ($36.2) had higher increments of 5.71% and 10.08%, respectively. Ireland ($33.2) grew by 5.5%, while Latvia ($19.9) and New Zealand ($18.3) posted significant increases of 7.44% and 17.7%, respectively. The last five years reveal a compound annual growth rate (CAGR) that highlights consistent upward trends in most countries.

Looking forward, increasing awareness, improved healthcare access, and global lifestyle shifts towards sedentary habits are expected to drive higher demand for diabetes medications. Emerging technologies and personalized medicine can further shape the market, meeting the nuanced needs of diverse populations. Close monitoring of healthcare policies and economic stability in these countries will also be critical in anticipating sales patterns.